UNICYCIVE THERAPEUTICS, INC. Operating Cash Flow
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Operating Cash Flow of -$13.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$7.60M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$6.24M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$8.03M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$5.96M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$31.32M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$28.57M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$18.28M.
- UNICYCIVE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$15.65M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$13.85M 10-Q · filed 2026-08-12 | -$21.88M derived: sum of 3 quarters · filed 2026-08-12 | -$27.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$6.24M 10-Q · filed 2026-05-12 | -$14.27M derived: sum of 2 quarters · filed 2026-05-12 | -$20.23M derived: sum of 3 quarters · filed 2026-05-12 | -$28.66M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$8.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$13.99M derived: sum of 2 quarters · filed 2026-03-30 | -$22.41M derived: sum of 3 quarters · filed 2026-08-12 | -$31.32M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$5.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$14.38M derived: sum of 2 quarters · filed 2026-08-12 | -$23.29M 10-Q · filed 2025-11-12 | -$29.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$8.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$17.32M 10-Q · filed 2026-08-12 | -$23.87M derived: sum of 3 quarters · filed 2026-08-12 | -$33.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$8.90M 10-Q · filed 2026-05-12 | -$15.45M derived: sum of 2 quarters · filed 2026-05-12 | -$24.70M derived: sum of 3 quarters · filed 2026-05-12 | -$31.02M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$15.80M derived: sum of 2 quarters · filed 2026-03-30 | -$22.12M derived: sum of 3 quarters · filed 2026-03-30 | -$28.57M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$9.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$15.57M derived: sum of 2 quarters · filed 2025-11-12 | -$22.03M 10-Q · filed 2025-11-12 | -$26.47M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$6.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$12.78M 10-Q · filed 2025-08-14 | -$17.21M derived: sum of 3 quarters · filed 2025-08-14 | -$21.64M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$6.46M 10-Q · filed 2025-05-14 | -$10.89M derived: sum of 2 quarters · filed 2025-05-14 | -$15.32M derived: sum of 3 quarters · filed 2025-05-14 | -$20.82M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$4.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$8.86M derived: sum of 2 quarters · filed 2025-03-31 | -$14.36M derived: sum of 3 quarters · filed 2025-03-31 | -$18.28M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$4.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$9.92M derived: sum of 2 quarters · filed 2024-11-13 | -$13.84M 10-Q · filed 2024-11-13 | -$19.93M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$5.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$9.42M 10-Q · filed 2024-08-14 | -$15.51M derived: sum of 3 quarters · filed 2024-08-14 | -$19.07M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$3.92M 10-Q · filed 2024-05-13 | -$10.00M derived: sum of 2 quarters · filed 2024-05-13 | -$13.57M derived: sum of 3 quarters · filed 2024-05-13 | -$16.61M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$9.65M derived: sum of 2 quarters · filed 2024-03-28 | -$12.69M derived: sum of 3 quarters · filed 2024-03-28 | -$15.65M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$3.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$6.61M derived: sum of 2 quarters · filed 2023-11-14 | -$9.57M 10-Q · filed 2023-11-14 | -$10.97M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$6.00M 10-Q · filed 2023-08-14 | -$7.41M derived: sum of 3 quarters · filed 2023-08-14 | -$10.88M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$2.96M 10-Q · filed 2023-05-16 | -$4.36M derived: sum of 2 quarters · filed 2023-05-16 | -$7.83M derived: sum of 3 quarters · filed 2023-05-16 | -$8.05M derived: sum of 4 quarters · filed 2023-05-16 |
| 2021-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$4.88M derived: sum of 2 quarters · filed 2023-03-31 | -$5.09M derived: sum of 3 quarters · filed 2023-03-31 | -$5.77M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$3.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$3.69M derived: sum of 2 quarters · filed 2022-11-14 | -$4.36M 10-Q · filed 2022-11-14 | -$4.90M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$217.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$890.00K 10-Q · filed 2022-08-15 | -$1.43M derived: sum of 3 quarters · filed 2022-08-15 | -$2.13M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$673.00K 10-Q · filed 2022-05-12 | -$1.21M derived: sum of 2 quarters · filed 2022-05-12 | -$1.92M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$538.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$1.24M derived: sum of 2 quarters · filed 2022-03-31 | -$1.46M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$706.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$921.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$215.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |